diseases are still the leading cause of mortality globally, even if in high-income countries other causes such as cancer are becoming more important. 1 It might be uncertain if the latter findings are caused by improved control of cardiovascular risk factors. However, recent data indicate that most non-fatal and fatal cardiovascular events around the world are preventable and can be attributed to a small number of common modifiable risk factors. 2 Despite increasing therapeutic options to target cardiovascular risk, most patients with established cardiovascular disease remain at an increased risk of major cardiovascular events. [3] [4] [5] [6] [7] Several large randomised trials such as COMPASS, 5 PEGASUS 6 or DAPT 7 have shown that intensified antithrombotic treatment strategies beyond the setting of acute myocardial infarction and/or coronary intervention are associated with a significant reduction of cardiovascular events. In contrast to dual antiplatelet strategies, the COMPASS trial did demonstrate that the combination of low-dose rivaroxaban with aspirin, as compared to aspirin alone, was even associated with a reduced all-cause mortality. 5 However, each of these treatment approaches was also associated with an increase in bleeding, which significantly reduced the net clinical benefit depending on how bleeding was weighted or what type of bleeding was included in these analyses. As bleeding is associated with a worse prognosis beyond the initial bleeding event, 8 current guidelines recommend a thoughtful weighting of ischaemic and bleeding risk before initiating such an intensified long-term anticoagulatory treatment. 3, 4 However, the identification of patients with a presumed net clinical benefit from such intensified treatment strategies can be challenging.
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The present analysis by Vanassche et al. provides additional insights into this difficult matter. 9 In this secondary analysis of the COMPASS trial, patients were stratified according to the number of insufficiently controlled and potentially modifiable cardiovascular risk factors. These were blood pressure (systolic 140 mmHg and/or diastolic 90 mmHg), active smoker, total cholesterol (150 mg/dL), diabetes mellitus, body mass index (25 or <20 kg/m 2 ) and level of physical activity (<150 minutes/week). Despite the widespread use of secondary prevention therapies in this trial, the number of risk factors at baseline was still a powerful predictor of subsequent vascular events. Patients with a lower number of cardiovascular risk factors showed a lower annual incidence of cardiovascular events. Even if the relative risk reduction of major vascular events associated with low-dose rivaroxaban and aspirin was similar across different strata, the absolute risk reduction increased with the rising number of risk factors.
The authors have to be congratulated for this comprehensive presentation of modifiable options that are associated with altered risk levels. As prospective and well-designed interventional studies targeting multiple modifiable risk factors are sparse, the present data provide important insights into how the day to day care of patients with established atherosclerotic disease might be affected and improved.
There are three items that should be highlighted:
. Over recent years, multiple novel antithrombotic, lipid-lowering, blood glucose level-reducing, or other (e.g. anti-inflammatory) strategies have been tested and have become available. Despite these therapeutic options targeting the high residual risk of patients in secondary prevention, simple preventive measures such as smoking cessation and weight reduction still appear to be of major importance. . Even if the risk of ischaemic events did increase with the number of risk factors, the risk of bleeding did not in patients only on aspirin or plateaued starting from two risk factors in patients on aspirin and rivaroxaban. This remarkable finding led to an Department of Cardiology and Angiology II, University Heart Center Freiburg, Germany increasing net clinical benefit in patients with a rising number of risk factors. . Moving one patient from a higher to a lower risk group (e.g. in most cases by reducing the number of modifiable risk factors by just one) appears to be similarly effective for the reduction of net clinical risk than adding low-dose rivaroxaban to aspirin (Figure 1 ). Even if this finding is of course not prospectively proved by the present data, it shows the potential of addressing a single modifiable risk factor (e.g. sufficient control of arterial hypertension or reduction of body weight) in apparently well treated populations.
In conclusion, the present data demonstrate that the number of easily assessable risk factors can predict the potential net clinical benefit of an intensified antithrombotic treatment strategy with low-dose rivaroxaban in secondary prevention. These data also show that even in apparently well treated populations, a significant number of patients still have multiple not sufficiently addressed modifiable risk factors. Even if these data are no proof that a reduction of cardiovascular risk by the optimal targeting of modifiable risk factors is similarly effective as intensifying the anticoagulatory treatment, the present data clearly show that there is a huge potential for risk reduction. As this approach is usually not associated with an increased risk of other events such as bleeding, this should always be the initial step. For patients remaining at high risk because the modification of multiple modifiable risk factors is not feasible, additional treatment strategies such as intensified antithrombotic treatment should be considered as demonstrated by COMPASS and recommended by current guidelines. [3] [4] [5] 
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